|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.52 | 88.89 | 103.80 | 0.54 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
1519.00
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Operational & Financial Ratios | | | | | | Earnings Per Share (Rs) | 30.60 | 35.73 | 25.35 | 28.75 | 23.44 | CEPS(Rs) | 37.98 | 42.50 | 31.16 | 36.19 | 30.51 | DPS(Rs) | 8.50 | 5.00 | 5.00 | 4.00 | 3.00 | Book NAV/Share(Rs) | 304.76 | 278.59 | 246.66 | 215.43 | 195.35 | Tax Rate(%) | 28.22 | 24.23 | 26.56 | 21.80 | 24.25 | Margin Ratios | | | | | | Core EBITDA Margin(%) | 22.93 | 22.77 | 25.21 | 19.82 | 19.18 | EBIT Margin(%) | 21.01 | 23.51 | 23.25 | 22.13 | 19.24 | Pre Tax Margin(%) | 20.85 | 23.34 | 22.88 | 21.87 | 19.11 | PAT Margin (%) | 14.96 | 17.69 | 16.80 | 17.10 | 14.48 | Cash Profit Margin (%) | 18.57 | 21.04 | 20.66 | 21.53 | 18.85 | Performance Ratios | | | | | | ROA(%) | 9.31 | 11.91 | 9.43 | 11.94 | 10.65 | ROE(%) | 10.49 | 13.61 | 10.97 | 14.00 | 12.67 | ROCE(%) | 14.71 | 18.05 | 15.15 | 18.08 | 16.69 | Asset Turnover(x) | 0.62 | 0.67 | 0.56 | 0.70 | 0.74 | Sales/Fixed Asset(x) | 2.19 | 2.29 | 1.81 | 2.15 | 2.20 | Working Capital/Sales(x) | 1.55 | 1.87 | 1.62 | 2.12 | 1.83 | Efficiency Ratios | | | | | | Fixed Capital/Sales(x) | 0.46 | 0.44 | 0.55 | 0.47 | 0.45 | Receivable days | 62.84 | 65.28 | 98.93 | 90.59 | 77.02 | Inventory Days | 74.79 | 73.59 | 91.60 | 79.30 | 82.64 | Payable days | 132.39 | 117.14 | 184.38 | 169.73 | 156.18 | Valuation Parameters | | | | | | PER(x) | 29.44 | 28.51 | 32.16 | 14.71 | 22.58 | PCE(x) | 23.71 | 23.96 | 26.16 | 11.69 | 17.35 | Price/Book(x) | 2.96 | 3.66 | 3.31 | 1.96 | 2.71 | Yield(%) | 0.94 | 0.49 | 0.61 | 0.95 | 0.57 | EV/Net Sales(x) | 4.54 | 5.25 | 5.74 | 2.65 | 3.43 | EV/Core EBITDA(x) | 16.88 | 18.44 | 19.67 | 9.33 | 13.79 | EV/EBIT(x) | 20.69 | 21.07 | 22.93 | 11.19 | 16.92 | EV/CE(x) | 2.60 | 3.17 | 2.82 | 1.65 | 2.31 | M Cap / Sales | 4.60 | 5.34 | 5.82 | 2.69 | 3.45 | Growth Ratio | | | | | | Net Sales Growth(%) | 2.66 | 36.08 | -10.72 | 2.30 | 8.64 | Core EBITDA Growth(%) | -2.94 | 32.76 | -8.40 | 16.91 | 21.70 | EBIT Growth(%) | -9.49 | 35.43 | -5.71 | 19.55 | 30.49 | PAT Growth(%) | -14.33 | 40.98 | -11.80 | 22.76 | 28.59 | EPS Growth(%) | -14.37 | 40.92 | -11.82 | 22.67 | 28.50 | Financial Stability Ratios | | | | | | Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Current Ratio(x) | 4.95 | 4.31 | 3.79 | 3.45 | 4.00 | Quick Ratio(x) | 3.74 | 2.98 | 2.64 | 2.29 | 2.79 | Interest Cover(x) | 128.33 | 142.27 | 62.77 | 83.23 | 147.90 | Total Debt/Mcap(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
|
|
|
|
|